U.S. Stem Cell, Inc.
USRMDelisted- Industry
- Services-Commercial Physical & Biological Research
- SEC CIK
- 0001388319
U.S. Stem Cell, Inc. was delisted in 2026; its insiders filed their last Form 4 on Apr 29, 2022; 1 institution reported holding it in 13F filings for Q2 2026, worth $11 in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 1
- Q2 2026, +1 vs. previous quarter
- 13F value
- $11
- Reported value at the end of Q2 2026
- Superinvestors holding
- 0
- At the end of Q2 2026
Superinvestors holding USRM, Q2 2026
No superinvestor reported holding USRM at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by U.S. Stem Cell, Inc. insiders from Form 4, newest first.
No open-market purchases or sales by U.S. Stem Cell, Inc. insiders are on file.
Top 10 13F holders, Q2 2026
The largest institutional positions in U.S. Stem Cell, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Wealthspire Advisors, LLC | 111,111 | $11 | 0.00% | +111,111 | New |